Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

The Role of Human Platelet-rich Plasma to Enhance the Differentiation of Adipose-derived Mesenchymal Stem Cells into Cardiomyocyte: An Experimental Study.

Suryawan IGR., Andrianto, Anggaraeni AD., Agita A., Nugraha RA.

Randomized Controlled Trial on Cardiovascular Disease, published in Cardiovasc Hematol Agents Med Chem (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Cardiovasc Hematol Agents Med Chem (2023)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
35538825
DOI
10.2174/1871525720666220510211116
Citations
2

Abstract (original English)

Several studies have shown that adipose-derived mesenchymal stem cells (AMSCs) can differentiate into mesenchymal lineages, including cardiac cell types, but complete differentiation into cardiomyocytes is challenging. Unfortunately, the optimal method to maximize AMSCs differentiation has not yet been established. Platelet-rich plasma (PRP), which contains rich growth factors, is believed to stimulate stem cell proliferation and differentiation in the context of cardiac tissue regeneration. This study aimed to analyze the effect of PRP administration to enhance the differentiation of AMSCs into cardiomyocytes. This study used a randomized post-test-only controlled group design. AMSCs were isolated from adipose tissues and cultured for 4 passages. The samples were divided into 3 groups, a negative control group (α-MEM), a positive control group (differentiation medium), and a treatment group (PRP). The assessment of GATA-4 expression was conducted using flow cytometry on day-5. The assessment of troponin expression was conducted using immunocytochemistry on day- 10. Data analysis was conducted using T-test and One-Way ANOVA. Flowcytometry of GATA-4 expression revealed a significant improvement in PRP group compared to negative and positive control group (67.04 ± 4.49 vs. 58.15 ± 1.23 p < 0.05; 67.04 ± 4.49 vs. 52.96 ± 2.02 p < 0.05). This was supported by the results of immunoc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMyocytes, CardiacCell DifferentiationPlatelet-Rich PlasmaAdipose TissueMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research